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items related to the financial aspect of caring. The objective was to test the French
translation of the PSQ III and evaluate its content validity considering the local
health care system. METHODS: The French version of the PSQ-III was tested on 5
patients with rheumatoid arthritis. The aim of these cognitive interviews was to
test clarity and comprehension of the translation but also the relevance of the 8
financial items to the French context from the patients’ point of view. RESULTS: A
direct translation of the financial items didn’t prove difficult as they could be ren-
dered literally. Cognitive interviews showed that the items were also easily under-
stood. Respondents mostly didn’t consider the items, however, as relevant to their
situation (e.g. “I worry sometimes about having to pay largemedical bills” or “I have
to pay for more of my medical care that I can afford”) although they showed some
concern regarding future evolution of the reimbursement process in France. After
consultation, the developer of the instrument confirmed that if needed, the items
related to the financial domain could be left aside. Decisionwasmade to create two
versions of the translation: one including the eight financial items and another
excluding them. CONCLUSIONS: As far as health care systems are concerned, lin-
guistic validation goes beyond understanding the text and direct translation of the
relevant items. It requires knowledge of the local context in order to collect mean-
ingful data. The target healthcare system needs to be carefully considered and
adequacy of the translation can be tested through cognitive interviews and con-
sultation with experts in the domain.
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OBJECTIVES: Fibromyalgia is a chronicmusculoskeletal condition characterized by
pain, fatigue, psychological distress, and sleep disturbances. The symptom com-
plexity and existence of comorbid conditions such as anxiety and depression have
been shown to negatively impact patient’s quality of life (QoL). The study objective
is to identify the most commonly used QoL instruments in fibromyalgia and to
examine the instruments’ psychometric properties. METHODS: A systematic
search was conducted from 1990 to 2010 using PUBMED, EBSCOhost, OVID, and
ScienceDirect databases. The search was limited to English language and key
search terms (e.g., fibromyalgia, quality of life) were used to identify articles of
interest. Articles identified were further screened to exclude clinical studies, re-
view papers and studies that discussed development of QoL instruments.
RESULTS: The search yielded 74 articles out of which 40 were included in the final
review. The review identified 11 generic instruments, 6 disease-specific, and 20
condition-specific instruments that were used in fibromyalgia. Short Form 36 was
the most commonly used generic instrument. Among disease-specific instru-
ments, Fibromyalgia Impact Questionnaire (FIQ) was themost commonly used and
has 10 domains (physical functioning, feeling well, work missed, job ability, pain,
fatigue, morning tiredness, stiffness, anxiety, depression). FIQ was found to have
good test-retest reliability (Pearson’s r  0.56-0.95) and construct validity. Beck
Depression Inventory was most commonly used condition-specific instrument.
Most of the reviewed studies assessed pain, fatigue, and sleep disorders using
visual analog scale.CONCLUSIONS: Fibromyalgiahas aprofound impact onpatient’s
quality of life. Among the QoL instruments reviewed, FIQ justifies its use in research
and clinical practice given its varied domains and strong psychometric properties.
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OBJECTIVES: To assess effects of etanercept therapy on vitality using the Health
Assessment Questionnaire (HAQ).METHODS: Eighty-nine patients with moderate
to severe rheumatoid arthritis (RA) were randomized in a phase 2/3 study to eval-
uate efficacy/safety of 25 mg etanercept twice weekly given in combination with
methotrexate. Fifty-nine patients were randomized to etanercept/methotrexate
and 30 to placebo/methotrexate. TheHAQwas administered at baseline, Days 8/15,
and every 4 weeks fromWeeks 424. Vitality was assessed using 4 items: Feel full
of pep? Feel worn out? Have enough energy to do the things you want to do? Feel
tired? Patients responded on a 5-point scale ranging fromAll the time toNever. Using
standard scoring algorithms, the vitality score ranged from 0 (worst) to 100 (best).
Anchor and distribution-basedmethods were employed to estimate theminimally
important difference (MID) for improvement. A repeatedmeasuresmodelwas used
to compare change frombaseline over time between groups. RESULTS:At baseline,
mean vitality scores were 34 with 95% confidence interval (CI) of 30 to 39 for etan-
ercept/methotrexate patients versus 40 (95% CI 33 to 47) for placebo/methotrexate
patients. At Week 24, the unadjusted mean improvements in vitality scores from
baseline were 22 (95% CI 17 to 28) for etanercept/methotrexate versus 8 (95% CI 2 to
15) for placebo/methotrexate patients. The MID was established at 9.0, and 37%
etanercept/methotrexate patients achieved the MID at Day 8 versus 17% placebo/
methotrexate patients. The percentage rose to 67% versus 42% at Week 12, and to
74% versus 38% at Week 24 for etanercept/methotrexate versus placebo/metho-
trexate patients, respectively. The repeated measures model indicated a statisti-
cally significant difference in vitality change from baseline over time between the
treatments (P  0.025). CONCLUSIONS: The vitality MID was achieved by 74% of
patients on etanercept/methotrexate by Week 24 versus 38% on placebo/metho-
trexate.
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OBJECTIVES: To examine willingness-to-pay (WTP) and factors influencing WTP
for treatment to prevent osteoporotic fractures with the stated preference data in
Korean population METHODS: A questionnaire was administered via a trained
interviewer to adult Korean general population. Subjects were selected by a non-
probability sampling via a quota-sampling to reflect the national distribution of
gender and age in Korea. Each respondent answered questions about eight differ-
ent scenarios, each of which specified as different types of fracture (hip and verte-
brae), efficacy of treatment (10% and 50%), and subjects to whom fracture occurred
(self and family). WTP per annumwas elicited with an open question per scenario.
The demographic characteristics of respondents were also collected. A multivari-
ate regression using a generalized linear model with a gamma distribution and
log-link function was performed to identify factors influencing the level of WTP.
RESULTS: Of one hundred and one respondents who completed the survey, the
average of WTP per annum for respondent itself was 550 USD and 1,125 USD for
treatment with 10% and 50% efficacy to reduce vertebral fracture risk, respectively.
Similarly, the average ofWTP per annum for respondent’s family member was 683
USD and 1,333 USD. The annualWTP for respondent itself was 1,017 USD and 1,950
USD for treatment with 10% and 50% efficacy to reduce hip fracture risk, respec-
tively. Education level, income level, the treatment efficacy, age, self-rated health
status, and subjects to whom fracture occurred were significantly associated with
the level of WTP. CONCLUSIONS: Respondents’ preferences for osteoporosis treat-
ment to reduce fracture risk reflected health and non-health related factors. This
research provides useful information to expand the coverage of osteoporosis treat-
ment which reduces the risk of costly fractures. Further research using a double-
bounded, dichotomous-choice type questions utilizing the WTP range based on
this study is ongoing.
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OBJECTIVES: To quantify the impact of etanercept (ETN) on work and activity
impairment in employed patients with moderate to severe rheumatoid arthritis
(RA) in US community practices. METHODS: In this prospective, observational
study, 55 sites across the US enrolled employed, TNF-naïve, moderate to severe RA
patients who initiated 50mg/week ETN between January 1, 2009 andMarch 5, 2010.
Telephone interviews were conducted at baseline (prior to or at the time of their
first ETN dose) and 6 months (after the start of ETN), collecting patient demo-
graphic and clinical information, in addition to evaluating work and activity im-
pairment using the Work Productivity and Activity Impairment Questionnaire
(WPAI). The change in WPAI outcomes after 6 months was assessed through a
Wilcoxon signed rank test on all enrolled patients. RESULTS: At baseline, 204 en-
rolled patients (mean age, 46.6 years (SD: 10.9); 72.6% female, 83.8% in full-time
employment; mean duration of RA, 5.2 years) reported that the overall work im-
pairment, work absenteeism, work presenteeism (reduction in productivity at
work) and total activity impairment due to RA were 43.2%, 9.9%, 39.7% and 56.1%,
respectively. All fourWPAI outcomes improved after initiation of ETN therapy. At 6
months, 153 patients remained on therapy and the overall respective WPAI scores
demonstrated a mean percent improvement from baseline of 28.7% (p0.0001),
54.6% (p0.0009), 33.2% (p0.0001) and 37.3% (p0.0001). In addition, mean hours
lost from work over the last 7 days because of RA decreased from 3.8 hours at
baseline to 1.6 hours at 6 months (62.5% decrease in hours lost; p0.0005).
CONCLUSIONS: In working patients with moderate to severe RA, ETN had a signif-
icant impact on reducing overall work impairment, absenteeism, presenteeism,
and activity impairment. Data demonstrate the positive impact of ETN on the
ability to work and perform regular activities when used under real world condi-
tions.
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OBJECTIVES: Estimate/compare employability-adjusted-life-years (EALYs) over time
for rheumatoid arthritis (RA) patients treated with golimumab (GLM)methotrexate
(MTX) vs. placeboMTX in the GO-FORWARD study.METHODS: GO-FORWARD is a
double-blind, placebo-controlled study of adults with active RA (4 tender and 4
swollen joints) and inadequate response to MTX. This analysis included patients
65yrs old who received placeboMTX (MTX) or GLM (50 or 100mg)MTX (GLM)
q4wks. Self-reported employment status and Health Assessment Questionnaire
(HAQ) were assessed through 3 years. A patient was ’unemployable’ if unemployed
and felt unable to work even if a job was available or ’employable’ if employed or
felt well enough to work if a job was available. Long-term (over a 10-yr period)
employability was estimated via logistic regression modeling incorporating age,
gender and HAQ. HAQ was derived using progression rates of 0.045/year for MTX
group and 0 (base case) to 0.025/year (sensitivity analysis) for GLM group. RESULTS:
At baseline, the mean HAQ score was 1.36, and 61.9% and 44.8% of patients 65
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